Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Is the AGM going to be posted online?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Comment by mstrmndon Aug 19, 2021 9:22pm
226 Views
Post# 33737974

RE:Is the AGM going to be posted online?

RE:Is the AGM going to be posted online? There was a really good scientific question about cytochrome p450 enzymes, where Dr. Stauffer mentioned possible genetic polymorphisms in the sulfotransferase enzyme as one possible explanation for the liver enzyme elevation, although not known yet

Also it was confirmed today the LTE was hepatocellular in nature, AST and/or ALT were elevated (not ALP, GGT, or bilirubin).  Confirmed LTE not due to COVID-19.  Dr. Stauffer didn't think LTE was related to vaccine.

And the best part? Dan's cha cha around a question about fast-tracking Otena for opioid replacement therapy :)

IrishCanuck wrote: I wanted to tune into the AGM but got busy. Looks like I missed a lot of messages with zero substance. Thanks Pez and Mstrnmnd for your summaries and comments :) I'd like to watch/listen it start to finish if possible 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities